Experience with 13 segmental pancreas transplants in cyclosporine-treated diabetic patients using ethibloc for duct obliteration (surgical aspects).
D000328:Adult; D003524:Cyclosporins / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D003928:Diabetic Nephropathies / Q000628:therapy*; D003973:Diatrizoate; D004338:Drug Combinations; D005227:Fatty Acids; D006801:Humans; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000628:therapy*; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016035:Pancreas Transplantation; D010180:Pancreatectomy / Q000379:methods; D010183:Pancreatic Ducts / Q000601:surgery*; D011183:Postoperative Complications / Q000209:etiology; D011409:Propylene Glycols; D011506:Proteins / Q000627:therapeutic use*; D014019:Tissue Donors; D015028:Zein
D003524:Cyclosporins; D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D011506:Proteins; D003973:Diatrizoate; D015028:Zein; C020481:alcoholic prolamine solution; D008775:Methylprednisolone